SEARCH

SEARCH BY CITATION

References

  • Ahmad R., Koole M., Evens N., Serdons K., Verbruggen A., Bormans G. and Van Laere K. (2013) Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [C]-NE40 in healthy subjects. Mol. Imaging Biol. [Epub ahead of print].
  • Ashton J. C. and Glass M. (2007) The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 5, 7380.
  • Bakos E., Evers R., Szakacs G. et al. (1998) Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 273, 3216732175.
  • Baumann C. A., Mu L., Johannsen S., Honer M., Schubiger P. A. and Ametamey S. M. (2010) Structure-activity relationships of fluorinated (E)-3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyloxime (ABP688) derivatives and the discovery of a high affinity analogue as a potential candidate for imaging metabotropic glutamate recepors subtype 5 (mGluR5) with positron emission tomography (PET). J. Med. Chem. 53, 40094017.
  • Benito C., Nunez E., Pazos M. R., Tolon R. M. and Romero J. (2007a) The endocannabinoid system and Alzheimer's disease. Mol. Neurobiol. 36, 7581.
  • Benito C., Romero J. P., Tolon R. M., Clemente D., Docagne F., Hillard C. J., Guaza C. and Romero J. (2007b) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 27, 23962402.
  • Console-Bram L., Marcu J. and Abood M. E. (2012) Cannabinoid receptors: nomenclature and pharmacological principles. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 415.
  • Dishino D. D., Welch M. J., Kilbourn M. R. and Raichle M. E. (1983) Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med. 24, 10301038.
  • Evens N. and Bormans G. M. (2010) Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography. Curr. Top. Med. Chem. 10, 15271543.
  • Evens N., Vandeputte C., Muccioli G. G., Lambert D. M., Baekelandt V., Verbruggen A. M., Debyser Z., Van Laere K. and Bormans G. M. (2011) Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging. Bioorg. Med. Chem. 19, 44994505.
  • Fernandez-Ruiz J., Romero J., Velasco G., Tolon R. M., Ramos J. A. and Guzman M. (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28, 3945.
  • Fujinaga M., Kumata K., Yanamoto K. et al. (2010) Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. Bioorg. Med. Chem. Lett. 20, 15651568.
  • Galiegue S., Mary S., Marchand J. et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 5461.
  • Gong J. P., Onaivi E. S., Ishiguro H., Liu Q. R., Tagliaferro P. A., Brusco A. and Uhl G. R. (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071, 1023.
  • Hammerle S. P., Rothen-Rutishauser B., Kramer S. D., Gunthert M. and Wunderli-Allenspach H. (2000) P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. Eur. J. Pharm. Sci. 12, 6977.
  • Hohmann A. G. and Herkenham M. (1999) Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90, 923931.
  • Honer M., Bruhlmeier M., Missimer J., Schubiger A. P. and Ametamey S. M. (2004) Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J. Nucl. Med. 45, 464470.
  • Horti A. G. and Van Laere K. (2008) Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain. Curr. Pharm. Des. 14, 33633383.
  • Horti A. G., Gao Y., Ravert H. T., Finley P., Valentine H., Wong D. F., Endres C. J., Savonenko A. V. and Dannals R. F. (2010) Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg. Med. Chem. 18, 52025207.
  • Kiferle L., Politis M., Muraro P. A. and Piccini P. (2011) Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur. J. Neurol. 18, 226231.
  • Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561564.
  • Milicevic Sephton S., Mu L., Schweizer W. B., Schibli R., Kramer S. D. and Ametamey S. M. (2012) Synthesis and evaluation of novel alpha-fluorinated (E)-3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyl oxime (ABP688) derivatives as metabotropic glutamate receptor subtype 5 PET radiotracers. J. Med. Chem. 55, 71547162.
  • Muccioli G. G. and Lambert D. M. (2006) Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin. Ther. Pat. 16, 14051423.
  • Munro S., Thomas K. L. and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 6165.
  • Onaivi E. S. (2009) Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int. Rev. Neurobiol. 88, 335369.
  • Pasquini S., De Rosa M., Pedani V. et al. (2011) Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. J. Med. Chem. 54, 54445453.
  • Pertwee R. G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129180.
  • Pertwee R. G. (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397411.
  • Price T. J., Helesic G., Parghi D., Hargreaves K. M. and Flores C. M. (2003) The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120, 155162.
  • Ramirez S. H., Hasko J., Skuba A. et al. (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 32, 40044016.
  • Rom S. and Persidsky Y. (2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J. Neuroimmune Pharmacol. 8, 608620.
  • Rossi S., Bernardi G. and Centonze D. (2010) The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp. Neurol. 224, 92102.
  • Ruhl T., Deuther-Conrad W., Fischer S., Gunther R., Hennig L., Krautscheid H. and Brust P. (2012) Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation. Org. Med. Chem. Lett. 2, 32.
  • Schatz A. R., Lee M., Condie R. B., Pulaski J. T. and Kaminski N. E. (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142, 278287.
  • Shoemaker J. L., Seely K. A., Reed R. L., Crow J. P. and Prather P. L. (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 101, 8798.
  • Sugiura T. and Waku K. (2002) Cannabinoid receptors and their endogenous ligands. J. Biochem. 132, 712.
  • Terry G. E., Hirvonen J., Liow J. S. et al. (2010) Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J. Nucl. Med. 51, 112120.
  • Thomas B. F., Gilliam A. F., Burch D. F., Roche M. J. and Seltzman H. H. (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther. 285, 285292.
  • Turkman N., Shavrin A., Ivanov R. A., Rabinovich B., Volgin A., Gelovani J. G. and Alauddin M. M. (2011) Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives. Bioorg. Med. Chem. 19, 56985707.
  • Turkman N., Shavrin A., Paolillo V. et al. (2012) Synthesis and preliminary evaluation of [18F]-labeled 2-oxoquinoline derivatives for PET imaging of cannabinoid CB2 receptor. Nucl. Med. Biol. 39, 593600.
  • Van Laere K. (2007) In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans. Eur. J. Nucl. Med. Mol. Imaging 34, 17191726.
  • Van Laere K., Goffin K., Casteels C., Dupont P., Mortelmans L., de Hoon J. and Bormans G. (2008) Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 39, 15331541.
  • Van Sickle M. D., Duncan M., Kingsley P. J. et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329332.
  • Wang Y., Seidel J., Tsui B. M., Vaquero J. J. and Pomper M. G. (2006) Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J. Nucl. Med. 47, 18911900.
  • Wanger-Baumann C. A., Mu L., Honer M., Belli S., Alf M. F., Schubiger P. A., Kramer S. D. and Ametamey S. M. (2011) In vitro and in vivo evaluation of [F-18]-FDEGPECO as a PET tracer for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). Neuroimage 56, 984991.
  • Wilson A. A., Jin L., Garcia A., DaSilva J. N. and Houle S. (2001) An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl. Radiat. Isot. 54, 203208.
  • Yiangou Y., Facer P., Durrenberger P., Chessell I. P., Naylor A., Bountra C., Banati R. R. and Anand P. (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6, 12.